Two Sigma Investments LP Sells 132,985 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Two Sigma Investments LP trimmed its holdings in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 41.5% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 187,126 shares of the specialty pharmaceutical company's stock after selling 132,985 shares during the quarter. Two Sigma Investments LP owned about 0.31% of Jazz Pharmaceuticals worth $23,045,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the business. IFP Advisors Inc bought a new stake in Jazz Pharmaceuticals during the fourth quarter valued at about $25,000. Quadrant Capital Group LLC boosted its holdings in Jazz Pharmaceuticals by 97.1% during the fourth quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company's stock valued at $25,000 after acquiring an additional 101 shares during the period. CoreFirst Bank & Trust bought a new stake in Jazz Pharmaceuticals during the fourth quarter valued at about $28,000. Allianz SE bought a new stake in Jazz Pharmaceuticals during the fourth quarter valued at about $29,000. Finally, Jones Financial Companies Lllp boosted its holdings in Jazz Pharmaceuticals by 75.1% during the fourth quarter. Jones Financial Companies Lllp now owns 303 shares of the specialty pharmaceutical company's stock valued at $37,000 after acquiring an additional 130 shares during the period. 89.14% of the stock is owned by institutional investors and hedge funds.

Jazz Pharmaceuticals Price Performance

Shares of NASDAQ JAZZ traded up $0.30 during mid-day trading on Tuesday, hitting $108.37. 314,986 shares of the stock were exchanged, compared to its average volume of 1,082,803. The company has a market cap of $6.68 billion, a P/E ratio of 15.26, a PEG ratio of 1.04 and a beta of 0.38. The stock's fifty day simple moving average is $112.19 and its two-hundred day simple moving average is $121.87. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. Jazz Pharmaceuticals plc has a twelve month low of $95.49 and a twelve month high of $148.06.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 earnings per share for the quarter, missing the consensus estimate of $4.65 by ($2.97). The firm had revenue of $897.84 million for the quarter, compared to analyst estimates of $984.16 million. Jazz Pharmaceuticals had a return on equity of 29.30% and a net margin of 11.60%. The business's quarterly revenue was down .5% on a year-over-year basis. During the same period in the previous year, the business posted $2.68 EPS. As a group, analysts forecast that Jazz Pharmaceuticals plc will post 16.96 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. Piper Sandler restated an "overweight" rating and set a $147.00 price target (down from $176.00) on shares of Jazz Pharmaceuticals in a report on Wednesday, May 7th. JPMorgan Chase & Co. increased their target price on shares of Jazz Pharmaceuticals from $200.00 to $209.00 and gave the company an "overweight" rating in a research note on Wednesday, February 26th. Robert W. Baird reduced their target price on shares of Jazz Pharmaceuticals from $167.00 to $155.00 and set an "outperform" rating for the company in a research note on Wednesday, May 7th. Royal Bank of Canada reduced their target price on shares of Jazz Pharmaceuticals from $182.00 to $172.00 and set an "outperform" rating for the company in a research note on Wednesday, May 7th. Finally, HC Wainwright increased their target price on shares of Jazz Pharmaceuticals from $200.00 to $217.00 and gave the company a "buy" rating in a research note on Monday, March 10th. Two analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to MarketBeat.com, Jazz Pharmaceuticals has a consensus rating of "Moderate Buy" and an average price target of $182.79.

Insider Transactions at Jazz Pharmaceuticals

In related news, CEO Bruce C. Cozadd sold 1,000 shares of the firm's stock in a transaction that occurred on Thursday, May 1st. The shares were sold at an average price of $116.35, for a total value of $116,350.00. Following the completion of the sale, the chief executive officer now owns 439,307 shares of the company's stock, valued at $51,113,369.45. This trade represents a 0.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Seamus Mulligan purchased 100,000 shares of the stock in a transaction that occurred on Friday, May 9th. The stock was bought at an average cost of $98.26 per share, with a total value of $9,826,000.00. Following the acquisition, the director now owns 100,000 shares of the company's stock, valued at $9,826,000. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last 90 days, insiders sold 28,236 shares of company stock valued at $3,956,190. Corporate insiders own 4.20% of the company's stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.